FATE today
$1.28-$0.06 (-4.48%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $3.21
Key levels
Resistance$1.84
Resistance$1.59
Support$1.25
Support$1.04
Latest news & SEC filings
NewsFate Therapeutics Shares New Clinical and Preclinical Findings at ACR Convergence 2026
ProductFate Therapeutics Reports 3 of 3 Lupus Patients Responded to FT819 Without Conditioning Chemotherapy
AnalystWells Fargo keeps Equal-Weight on Fate Therapeutics, cuts target to $3
All FATE news →About Fate Therapeutics
Fate Therapeutics is a biopharmaceutical firm in the clinical stage of development that creates cell-based medicines from reprogrammed stem cells. Its candidates include engineered T cells and natural killer cells designed to treat autoimmune conditions and solid tumors, with lead programs aimed at CD19 and HER2. The company runs its own production site and works with partners including Ono Pharmaceutical.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
FATE THERAPEUTICS INC (FATE)
What Is the Price Target for FATE?
SEPT Low Target
$3.50
SEPT Mid Target
$7.00
SEPT High Target
$7.00
Analyst Consensus
$7.00
Is FATE a Buy or Sell Right Now?
Thesis
- •Revenue growing -51.2% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for FATE.
Start Free Trial →Is FATE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.08
0
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with FATE?
Insider Signal
SELLING
0 buys / 5 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Adawi Kamal | officer | Sale | 6,582 | $14K | Nov 3, 2026 |
| TAHL CINDY | officer | Sale | 25,590 | $48K | May 20, 2026 |
| Valamehr Bahram | director officer | Sale | 28,946 | $54K | May 20, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →FATE Growth Story
Revenue YoY
-51.2%
3yr Revenue CAGR
-59.0%
EPS Growth YoY
29.88%
FCF Growth YoY
9.4%
Revenue Trend
DECLINING
Dark Pool Trades for FATE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for FATE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:05:18 | $1.26 | 9,000 | $$11K | SELL |
| 21:26:01 | $1.28 | 20,445 | $$26K | BUY |
| 20:58:12 | $1.28 | 1,991 | $$3K | BUY |
| 20:57:08 | $1.27 | 1,600 | $$2K | MIDPOINT |
| 20:57:01 | $1.27 | 1,998 | $$3K | MIDPOINT |
5 dark pool trades shown · $$45K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for FATE
PREVIEWSEPT Investing provides real-time options flow tracking for FATE, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1.5 | May 21 | 189 | $$30 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About FATE
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for FATE. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$FATE earnings are scheduled for Thu Nov 12. 📅
Join 3,500+ traders discussing FATE in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for FATE THERAPEUTICS INC (FATE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →FATE — frequently asked questions
What is FATE stock price today?
FATE THERAPEUTICS INC (FATE) is at $1.28, down 4.48% (-$0.06) at the Nov 13, 2026 close.
Why is FATE stock moving today?
Latest FATE news — Nov 11, 2026: Fate Therapeutics Shares New Clinical and Preclinical Findings at ACR Convergence 2026 · Nov 10, 2026: Fate Therapeutics Reports 3 of 3 Lupus Patients Responded to FT819 Without Conditioning Chemotherapy
Why did FATE stock move on Oct 26, 2026?
Fate Therapeutics presented updated preliminary Phase 1 data for FT819, its off-the-shelf anti-CD19 CAR T-cell candidate, in patients with active lupus nephritis at ASN Kidney Week 2026, with two headlines highlighting the results. Despite the bullish sentiment around the clinical update, the stock closed at $2.06, down 2.14% on the day, trading between $2.04 and $2.14 on volume of 1,366,535 shares.
What is the FATE price target?
The average analyst price target for FATE is $7.00, ranging from $4 to $7, based on 3 analysts.
What do analysts rate FATE?
Analyst ratings for FATE: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did FATE beat earnings?
FATE last reported on Aug 13, 2026: EPS -$0.25 vs -$0.25 expected — a beat of 1.4%.
Does FATE pay a dividend?
FATE does not currently pay a dividend.
What are FATE support and resistance levels?
Support: $1.25, $1.04. Resistance: $1.59, $1.84, $2.23.
What are insiders doing with FATE?
Insider activity: SELLING, 0 buys and 5 sells in the last 90 days.
What is the latest news on FATE?
Nov 11, 2026: Fate Therapeutics Shares New Clinical and Preclinical Findings at ACR Convergence 2026 · Nov 10, 2026: Fate Therapeutics Reports 3 of 3 Lupus Patients Responded to FT819 Without Conditioning Chemotherapy · Nov 6, 2026: Wells Fargo keeps Equal-Weight on Fate Therapeutics, cuts target to $3